Targeting B and T Lymphocyte Attenuator Regulates Lupus Disease Development in NZB/W Mice.

IF 6.2 Q1 IMMUNOLOGY
ImmunoTargets and Therapy Pub Date : 2025-01-17 eCollection Date: 2025-01-01 DOI:10.2147/ITT.S490573
Léa Gherardi, Lucie Aubergeon, Mélanie Sayah, Jean-Daniel Fauny, Hélène Dumortier, Fanny Monneaux
{"title":"Targeting B and T Lymphocyte Attenuator Regulates Lupus Disease Development in NZB/W Mice.","authors":"Léa Gherardi, Lucie Aubergeon, Mélanie Sayah, Jean-Daniel Fauny, Hélène Dumortier, Fanny Monneaux","doi":"10.2147/ITT.S490573","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The co-inhibitory receptor B and T Lymphocyte Attenuator (BTLA) negatively regulates B and T cell activation. We have previously shown an altered BTLA expression by regulatory T cells and an impaired capacity of BTLA to inhibit CD4<sup>+</sup> T cell activation in lupus patients. In this study, we analyzed BTLA expression and function in the NZB/W lupus-mouse model and examined the therapeutic potential of BTLA targeting.</p><p><strong>Methods: </strong>BTLA expression and function were analyzed in young (10-12-week-old) and old-diseased NZB/W mice (>35-week-old with proteinuria) in comparison to age-related BALB/W control mice. 20-22 weeks old NZB/W mice (n=10) were injected i.p with 3 mg/kg, twice a week for ten weeks, with the anti-BTLA antibody 6F7 or its isotype control.</p><p><strong>Results: </strong>In old-diseased NZB/W mice, BTLA expression is slightly modified in B cell subsets whereas CD4<sup>+</sup> T cells display impaired BTLA functionality. Administration of the 6F7 anti-BTLA antibody into 20-22 week-old NZB/W mice resulted in a delayed onset of proteinuria (p<0.01), limited kidney damages (p<0.05) and an increased survival rate (p<0.01) compared to isotype-treated mice. This beneficial effect was associated with a decrease in circulating B cell and spleen follicular B cell numbers. Regarding its mode of action, we demonstrated that the 6F7 antibody is not a depleting antibody and does not block HVEM binding to BTLA, but instead induces BTLA down modulation and exhibits in vivo agonist activity.</p><p><strong>Conclusion: </strong>Overall, our data confirm the involvement of BTLA in lupus pathogenesis and provide the first evidence that BTLA is a potential therapeutic target for the treatment of lupus.</p>","PeriodicalId":30986,"journal":{"name":"ImmunoTargets and Therapy","volume":"14 ","pages":"7-23"},"PeriodicalIF":6.2000,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750947/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ImmunoTargets and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/ITT.S490573","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: The co-inhibitory receptor B and T Lymphocyte Attenuator (BTLA) negatively regulates B and T cell activation. We have previously shown an altered BTLA expression by regulatory T cells and an impaired capacity of BTLA to inhibit CD4+ T cell activation in lupus patients. In this study, we analyzed BTLA expression and function in the NZB/W lupus-mouse model and examined the therapeutic potential of BTLA targeting.

Methods: BTLA expression and function were analyzed in young (10-12-week-old) and old-diseased NZB/W mice (>35-week-old with proteinuria) in comparison to age-related BALB/W control mice. 20-22 weeks old NZB/W mice (n=10) were injected i.p with 3 mg/kg, twice a week for ten weeks, with the anti-BTLA antibody 6F7 or its isotype control.

Results: In old-diseased NZB/W mice, BTLA expression is slightly modified in B cell subsets whereas CD4+ T cells display impaired BTLA functionality. Administration of the 6F7 anti-BTLA antibody into 20-22 week-old NZB/W mice resulted in a delayed onset of proteinuria (p<0.01), limited kidney damages (p<0.05) and an increased survival rate (p<0.01) compared to isotype-treated mice. This beneficial effect was associated with a decrease in circulating B cell and spleen follicular B cell numbers. Regarding its mode of action, we demonstrated that the 6F7 antibody is not a depleting antibody and does not block HVEM binding to BTLA, but instead induces BTLA down modulation and exhibits in vivo agonist activity.

Conclusion: Overall, our data confirm the involvement of BTLA in lupus pathogenesis and provide the first evidence that BTLA is a potential therapeutic target for the treatment of lupus.

靶向B和T淋巴细胞衰减剂调控狼疮疾病在NZB/W小鼠中的发展。
目的:共抑制受体B和T淋巴细胞衰减剂(BTLA)负调控B和T细胞的活化。我们之前已经在狼疮患者中证明了调节性T细胞改变了BTLA的表达,并且BTLA抑制CD4+ T细胞激活的能力受损。在本研究中,我们分析了BTLA在NZB/W狼疮小鼠模型中的表达和功能,并研究了BTLA靶向的治疗潜力。方法:与年龄相关的BALB/W对照组小鼠比较,分析年轻(10-12周龄)和老年患病NZB/W小鼠(> - 35周龄伴蛋白尿)BTLA的表达和功能。将20 ~ 22周龄的NZB/W小鼠(n=10)腹腔注射抗btla抗体6F7或其同型对照,剂量为3 mg/kg,每周2次,连续10周。结果:在老年患病的NZB/W小鼠中,BTLA在B细胞亚群中的表达略有改变,而CD4+ T细胞显示BTLA功能受损。在20-22周龄的NZB/W小鼠中注射6F7抗BTLA抗体可延迟蛋白尿的发生(结论:总体而言,我们的数据证实了BTLA参与狼疮的发病机制,并首次提供了BTLA是治疗狼疮的潜在治疗靶点的证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
16.50
自引率
0.00%
发文量
7
审稿时长
16 weeks
期刊介绍: Immuno Targets and Therapy is an international, peer-reviewed open access journal focusing on the immunological basis of diseases, potential targets for immune based therapy and treatment protocols employed to improve patient management. Basic immunology and physiology of the immune system in health, and disease will be also covered.In addition, the journal will focus on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信